TTranscat provides calibration services and distributes test and measurement equipment across North America. It began as a tool manufacturer, then became a distributor, and later focused on high-value services by opening calibration labs to ensure instruments meet precise standards. Their products and services work by calibrating instruments in trusted labs to national or industry standards, offering traceable, documented calibration results and related support. The company differentiates itself through a nationwide service network and growth via strategic acquisitions, expanding its geographic reach and technical capabilities in tightly regulated sectors such as life sciences, aerospace, and energy. Its goal is to help customers maintain accurate, compliant measurement tools and equipment, enabling reliable operations in highly regulated industries.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Town of Ogden, New York
Founded
1964
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$150.3M
Above
Industry Average
Funded Over
2 Rounds
Why is Transcat (TRNS) stock soaring today. Anthony lee /. November 4, 2026 What happened? Shares of measurement equipment distributor Transcat (NASDAQ:TRNS) jumped 18.9% in the morning session after the company reported strong third-quarter 2026 financial results, highlighted by an 18% increase in total revenue to $97.1 million. According to a company press release, Transcat reported that service revenue rose 23% to $64.8 million, with service gross margin expanding 220 basis points to 34%. Distribution revenue climbed 10% to $32.3 million, driven by strong rental demand across its markets. Beyond top-line expansion, the company delivered adjusted earnings of $0.64 per share, outpacing Wall Street consensus estimates of $0.45 per share. Operating margin remained stable at 5.2%, matching the same period last year, while adjusted EBITDA reached $14.91 million to beat analyst projections. What is the market telling us. Transcat's shares are quite volatile and have had 19 moves greater than 5% over the last year. But moves this big are rare even for Transcat and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 12 months ago when the stock dropped 12% on the news that the company reported mixed third-quarter 2025 results that showed a miss on earnings per share and a steep decline in profit. While revenue grew by 21.3% to $82.3 million and surpassed expectations, investors focused on the weaker aspects of the report. The company's adjusted earnings per share of $0.44 missed analyst forecasts. More significantly, net income experienced a sharp decrease of 61.4% to $1.3 million compared to the prior year. This drop in profitability was linked to higher operating expenses from recent acquisitions. The company's operating margin also compressed, falling to 4.3% from 5.5% in the same quarter last year. Transcat is up 87.5% since the beginning of the year, and at $107.18 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Transcat's shares 5 years ago would now be looking at an investment worth $1,252. ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you're unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Transcat Q2 earnings call highlights. Transcat (NASDAQ:TRNS) reported fiscal second-quarter 2027 revenue growth of 18% as demand remained strong across its calibration services and distribution businesses, prompting the company to raise its full-year outlook for service organic revenue growth. Consolidated revenue rose to $97.1 million in the quarter. Gross profit increased 22% to $32.6 million, while consolidated gross margin expanded 110 basis points to 33.6%. Net income grew 90%, and diluted earnings per share rose 79% to $0.25. On an adjusted basis, diluted EPS increased 46% year over year to $0.64. "The fiscal second quarter of 2027 marked another sequential quarter of strong financial performance, led by strength in our calibration business," President and CEO Jaime Irick said. He said the company believes it is gaining market share through organic growth, acquisitions and a more productive sales organization. Service segment drives growth and margin expansion. Service revenue increased 23% to $64.8 million, including 16% organic growth. The company said the quarter marked its 70th consecutive quarter of year-over-year service revenue growth. Service gross profit climbed 31%, and service gross margin expanded 220 basis points from the prior-year period to 34.4%. Irick attributed the improvement to operating leverage, operational initiatives, pricing, business mix and the maturation of new customer relationships. He said Transcat is focused on improving customer-facing processes, applying Lean principles and using technology, including artificial intelligence, to improve productivity. During the question-and-answer session, Chief Financial Officer Tom Barbato said the broader calibration market was growing at approximately 4% to 6%, while Transcat's service growth reflected pricing gains of roughly a couple of percentage points and market-share gains. He said growth was broad-based across geographies and end markets. Irick said the company's sales organization has become more focused on upstream performance measures, including pipeline development, win rates and customer retention. He added that Transcat is seeing continued demand in regulated markets such as life sciences, aerospace and defense, and energy. Management raised its fiscal 2027 outlook for service organic revenue growth to the low-double-digit range, up from its prior forecast for high-single-digit growth. The company also continues to expect service gross-margin expansion for the full year, including at least 100 basis points of year-over-year expansion in the second half. Distribution growth supported by rentals. Distribution revenue grew 10% to $32.3 million, driven by rental-channel demand and product sales. Distribution gross profit increased 6%, while gross margin was 32%, improving sequentially from 31.4% in the fiscal first quarter but declining from the prior-year period. Barbato said the year-over-year margin decline reflected sales of lower-margin used equipment, which enabled the company to reinvest in its rental asset portfolio. He said Transcat expects distribution margins to improve year over year in the second half of fiscal 2027, supported by the higher-margin rental business. The company expects its rental business to grow at a low-double-digit rate over time. Barbato said the company periodically sells underutilized rental assets to free capital for reinvestment in equipment with stronger yields. Management also identified energy as a source of demand, including power generation, power consumption, transmission and distribution, and electric-vehicle charging infrastructure. Barbato said data-center expansion has so far represented a larger opportunity for Transcat's rental and distribution business than for calibration services, though management expects it to be a future tailwind. M&A remains central to strategy. Transcat highlighted its August acquisition of Southeastern Biomedical Associates, which serves hospital networks across the southeastern U.S. and other markets. Irick said the acquisition expands the company's biomedical calibration footprint in high-cost-of-failure applications where accredited calibration is important for patient safety and regulatory compliance. Management said Southeastern's culture, customer focus and quality standards align closely with Transcat's. The company has also invested capital to expand Southeastern's capabilities and support growth among its existing customers. Irick said acquisitions will remain a core part of Transcat's growth strategy alongside organic expansion. He noted that the company has acquired 14 businesses over the past five years, with all but one completed through proprietary processes. Management is working to further strengthen its integration processes and to identify opportunities in adjacent regulated, recurring-revenue markets. * Adjusted EBITDA increased 23% to $14.9 million. * Adjusted EBITDA margin expanded 70 basis points to 15.4%. * Service adjusted operating income increased 45% to $10.6 million. * Operating free cash flow for the first six months rose 46% to $10.9 million. * At quarter-end, total debt was $116.9 million and the leverage ratio was 2.18 times. Irick said Transcat sees a path toward $500 million in revenue and continued margin expansion over the next three to five years, supported by organic growth, acquisitions and expansion of its rental business. About Transcat (NASDAQ:TRNS). Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets. Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.
Transcat (NASDAQ:TRNS), a measurement equipment distributor, reports third-quarter results on Tuesday after market close. Analysts expect revenue to grow 12.4% year on year, slowing from 21.3% in the same quarter last year. Last quarter, Transcat beat revenue estimates with $92.95 million, up 21.6%, though it has missed Wall Street's revenue estimates multiple times over the past two years. Peers have reported already. WESCO's revenue rose 16.6%, beating estimates by 5.1%, and Fastenal's rose 15.5%, topping estimates by 1%. Both stocks fell afterwards. Transcat shares are down 4.7% over the last month, at $86.34. The average analyst price target is $107.
Transcat stock fell below its 200-day moving average. Published on 10/18/2026 at 13:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Revenue rose 21.6 percent to USD 92.95 million in the quarter. Transcat stock had a USD 752.1 million market value on October 16, 2026. Technical signal and earnings context. * Transcat fell below its USD 85.11 200-day average on October 16, 2026. * Quarterly revenue reached USD 92.95 million after a 21.6 percent year-over-year increase. * Transcat had a USD 752.1 million market value as of October 16, 2026. Transcat, Inc. (US8935291075) fell below its 200-day moving average of USD 85.11 during trading on October 16, 2026, according to MarketBeat. The technical break followed a quarterly earnings update that showed strong revenue growth but a sharp market focus on valuation and execution. Discover more Compare Lab Gear Find Multimeters Source Materials Three events shape the stock. The chronology is clear. On August 4, 2026, Transcat reported quarterly earnings per share of USD 0.51 against a USD 0.38 consensus estimate, with revenue of USD 92.95 million versus USD 86.55 million expected, according to MarketBeat. On August 5, 2026, Northland Securities lowered its rating from outperform to market perform and set a USD 95.00 price objective. On October 16, 2026, the stock crossed below its USD 85.11 200-day average and last traded at USD 80.35 on Nasdaq. What did earnings add? The quarter delivered a quantified operating improvement. Revenue increased 21.6 percent year over year to USD 92.95 million, while the result exceeded the revenue consensus of USD 86.55 million by USD 6.40 million, or 7.40 percent, according to Yahoo Finance. Earnings per share also exceeded the USD 0.38 estimate by USD 0.13. That operating performance sits beside a demanding valuation backdrop. MarketBeat reported a 0.99 percent net margin and a 5.56 percent return on equity for the quarter, while its analyst overview showed a consensus rating of Reduce and a USD 95.00 average price target. Calibration remains the core business. Transcat provides calibration, repair, testing and compliance services for test, measurement and control equipment. Its investor-relations materials describe two complementary activities, Service and Distribution, serving regulated customers in life sciences, manufacturing and other technical markets, according to Transcat. Market value sets the frame. Transcat had a market capitalization of USD 752.1 million and a 52-week range of USD 50.23 to USD 100.00 as of October 16, 2026. The distance between the latest Nasdaq price and the 200-day average makes the technical signal relevant, while the latest revenue beat supplies a counterweight. The next investor debate therefore centers on whether revenue growth can translate into stronger profitability. The reported 0.99 percent net margin leaves execution as the key operating measure. The further course of trading is shown by the continuously updated real-time quote of Transcat stock. Transcat facts. * Company: Transcat, Inc. * ISIN: US8935291075 * Ticker: TRNS * Primary exchange: Nasdaq * Market capitalization: USD 752.1 million (as of October 16, 2026) * 52-week range: USD 50.23-100.00 (as of October 16, 2026) * Sector / Industry: Industrials / Specialty Business Services Discover more Invest in Stocks Sponsored Ad Transcat stock: new analysis - 24 October. Fresh Transcat information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US8935291075 | TRNS | boerse | 70353325 | bgmi
Transcat expands biomedical business with $12.8M acquisition. Rochester-based Transcat Inc. is expanding its biomedical calibration business into the southeastern U.S. with the $12.8 million acquisition of a North Carolina company that serves hospitals and health care facilities. Transcat announced this week that it acquired privately held Southeastern Biomedical Associates Inc. The purchase price was paid in cash and is subject to customary adjustments and holdback provisions. Founded in 1996 and based in Granite Falls, North Carolina, Southeastern provides calibration, repair, preventive maintenance, electrical safety inspections, documentation and regulatory compliance services to hospital networks and other health care facilities throughout the Southeast and beyond. The company also sells biomedical equipment, patient-ready accessories and equipment parts. Its services include helping customers acquire equipment and liquidate assets. The acquisition builds on Transcat's existing biomedical business while expanding its geographic reach in a market the company expects to grow, according to company leaders. For Transcat, the deal is part of a broader strategy to build scale in highly regulated industries where equipment failures can carry significant financial, operational and safety consequences. "The acquisition of Southeastern Biomedical reinforces Transcat's strategy of deepening our presence in the Life Science sector, one of the most regulated and mission-critical end markets we serve," said Jaime Irick, Transcat's president and CEO. Transcat has more than 30 calibration laboratories across North and Central America. The company sees that footprint as a competitive advantage as hospital networks and other regulated customers increasingly need consistent, accredited calibration services across multiple locations. Irick said Southeastern's reputation and customer base will allow Transcat to serve a larger geography while maintaining its focus on quality and turnaround times. The acquisition also brings Southeastern's employees and owners into Transcat. Co-owners Boyd Campbell and Greg Johnson will join the company. Southeastern has built its business over more than three decades serving customers throughout the Southeast and beyond, Johnson said. He said Transcat was the right partner to support the company's next phase of growth. "Transcat has developed a reputation in this industry for treating acquired employees and customers right," Johnson said, adding that he and Campbell look forward to being part of the future of Transcat Biomedical. The acquisition comes as Transcat continues to emphasize mergers and acquisitions as part of its growth strategy. Irick said the combination should create opportunities to expand service across the companies' customer bases while maintaining what he described as industry-leading turnaround times.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Town of Ogden, New York
Founded
1964
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs